RushDATA™ Delivers Wet-Lab Validation for AI-Designed Antibodies from Molence Bio’s Mol-1

via Business Wire
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Biointron Biological USA Inc. ("Biointron") is proud to have supported Molence Bio's Mol-1 project. Mol-1 matches the performance of the leading closed-source model IsoDDE in antibody-antigen structure prediction and can design functional nanobodies from scratch. To show those designs can become real drug candidates, Biointron ran the developability assays using RushDATA™, our wet-lab validation service for AI-designed antibodies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111145071/en/

RushDATA™ Delivers Wet-Lab Validation for AI-Designed Antibodies from Molence Bio’s Mol-1

RushDATA™ Delivers Wet-Lab Validation for AI-Designed Antibodies from Molence Bio’s Mol-1

The results: 23 of 30 AI-designed candidates met at least three of four developability criteria.

Wet-Lab Validation by Biointron

An AI-designed antibody needs lab data to prove it can become a drug. Biointron ran the developability panel on Molence Bio's VHH-Fc candidates, measuring properties that predict manufacturability and safety, including hydrophobicity, thermal stability, self-interaction, and non-specific binding.

Each assay was benchmarked against Biointron reference antibodies, including infliximab, bevacizumab, bococizumab, gantenerumab and trastuzumab, so the designs could be compared directly with approved and clinical-stage antibodies.

Closing the Loop Between AI and the Lab

RushDATA™ is Biointron’s wet-lab validation service for AI-designed antibodies, combining a capacity of 10,000+ antibodies per day with sequence-to-data turnaround in as little as 2 days with cell-free expression or 3 days with CHO expression.

The service offers multi-point binding affinity measurements by BLI or SPR, alongside developability profiling using DSF, PSR-BVP, and AC-SINS. Results are delivered as structured, model-ready datasets with API access, allowing experimental findings to feed directly into the next round of AI-guided design.

Why It Matters Now

AI can now generate antibody binders at scale. The next challenge is proving which designs work in the lab and behave like drugs. Mol-1 shows what happens when a strong open model meets high-quality experimental data, and Biointron is proud to provide that data.

Biointron congratulates Molence Bio on the launch of Mol-1 and looks forward to supporting the researchers who build on it.

About Biointron

Founded in 2012, Biointron is a global antibody discovery CRO trusted by 3,000+ organizations in 20+ countries and regions, including top 20 pharma companies. Our RushDATA™ platform generates wet-lab data for AI-designed antibodies at scale, expressing 10,000+ antibodies a day and delivering binding and developability results in as little as 2 days, ready to feed your models via API. We also offer end-to-end antibody services from discovery to large-scale production. Several partner projects using our CHOK1BN cell line have entered multicenter international clinical trials successfully.

Learn more about RushDATA™: https://www.biointron.com/antibody-production/rushdata.html

About Molence Bio

Molence Bio is an AI-native biotech built on their own biomolecular foundation models. Their biologists, chemists, and AI researchers work side by side to advance these models and apply them to drug discovery: unlocking targets long considered undruggable, designing better molecules, and building a pipeline of therapies for unmet medical needs.

Access the model weights: https://github.com/molence/Mol-1

Contacts

Biointron
+1 (732) 790-8340
info@biointron.com
20 University Road, Suite 500, Cambridge, MA 02138

Media contact: Mia Deng

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article